Table 1.

Expression of EHMT2 in Cancer Tissues Analyzed by cDNA Microarray^*.

Tissue Type	Case (n)	Ratio (Tumor/Normal)
		Count > 2	Count > 3	Count > 5
Acute myelogenous leukemia	55	26 (47.3%)	8 (14.5%)	1 (1.8%)
Bladder cancer	34	19 (55.9%)	11 (32.4%)	4 (11.8%)
Breast cancer	78	14 (17.9%)	4 (5.1%)	3 (3.8%)
Cervical Cancer	19	5 (26.3%)	1 (5.3%)	0 (0%)
Chronic myelogenous leukemia	77	46 (59.7%)	40 (51.9%)	19 (24.7%)
Esophageal cancer (SqCC)	64	23 (35.9%)	15 (23.4%)	7 (10.9%)
Non-small cell lung cancer	35	17 (48.6%)	11 (31.4%)	3 (8.6%)
Osteosarcoma	27	9 (33.3%)	4 (14.8%)	3 (11.1%)
Small cell lung cancer	15	11 (73.3%)	3 (20%)	1 (6.7%)

^*We compared the signal intensity EHMT2 between tumor tissues and corresponding nonneoplastic tissues derived from the same patient.